Measles virus vaccine expressing SARS-CoV-2 protein(s)
A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.
1. A method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus in a subject comprising administering a recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein to the subject, wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-CoV-2 spike glycoprotein.
2. The method of claim 1 , wherein the recombinant measles viral vector is a recombinant Edmonston-Zagreb (EZ) measles viral vector.
3. The method of claim 1 , wherein the nucleic acid sequence has been codon optimized.
4. The method of claim 1 , wherein the ER retention sequence of the SARS-CoV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail.
5. The method of claim 1 , wherein the nucleic acid sequence encoding the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 3 (S-CO-AA).
6. The method of claim 1 , wherein the SARS-CoV-2 spike glycoprotein comprises the amino acid sequence of SEQ ID NO: 10 (S-CO-AA).
7. The method of claim 1 , wherein the recombinant measles viral vector comprises the nucleic acid sequence of SEQ ID NO: 17 (SARS-CoV-2-S-CO-AA).
8. A method for inducing an immune response against a coronavirus in a subject comprising administering a recombinant measles viral vector comprising a nucleic acid sequence encoding a SARS-CoV-2 spike glycoprotein to the subject, wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-CoV-2 spike glycoprotein.
9. The method of claim 1 , wherein the subject is a human subject.
10. The method of claim 1 , wherein the recombinant measles viral vector is administered by oral, sublingual, buccal, intradermal, parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, or interperitoneal administration.
11. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10 (S-CO-AA).
12. A pharmaceutical composition comprising (i) the polypeptide of claim 11 , a nucleic acid encoding the polypeptide, or a recombinant vector comprising the nucleic acid and (ii) a pharmaceutically acceptable carrier.
13. A method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus in a subject comprising administering the polypeptide of claim 11 , a nucleic acid encoding the polypeptide, a recombinant vector comprising the nucleic acid, or a pharmaceutical composition thereof to the subject.
14. A method for inducing an immune response against a coronavirus in a subject comprising administering the polypeptide of claim 11 , a nucleic acid encoding the polypeptide, a recombinant vector comprising the nucleic acid, or a pharmaceutical composition thereof to the subject.
15. The method of claim 8 , wherein the recombinant measles viral vector is a recombinant Edmonston-Zagreb (EZ) measles viral vector.
16. The method of claim 8 , wherein the nucleic acid sequence has been codon optimized.
17. The method of claim 8 , wherein the ER retention sequence of the SARS-CoV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail.
18. The method of claim 8 , wherein the nucleic acid sequence encoding the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 3 (S-CO-AA).
19. The method of claim 8 , wherein the SARS-CoV-2 spike glycoprotein comprises the amino acid sequence of SEQ ID NO: 10 (S-CO-AA).
20. The method of claim 8 , wherein the recombinant measles viral vector comprises the nucleic acid sequence of SEQ ID NO: 17 (SARS-CoV-2-S-CO-AA).